Introduction or Discontinuation of Additional Risk Minimisation Measures During the Life Cycle of Medicines in Europe

ConclusionsWe found low probabilities of introduction and discontinuation of aRMMs (excluding DHPCs) during the product life cycle for medicines authorised between 2006 and 2017. The low rate of discontinuation may potentially be due to a lack of robust data on effectiveness of aRMMs. Further research is needed to get more insight into the dynamics of aRMMs during the medicine life cycle.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research